Neogen Corporation
NASDAQ:NEOG · NASDAQ Global Select
+$0.16 today
Vol 3.41M · Avg 2.53M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$1.1B -11491.6% | -$9.4M +58.8% | -$22.9M -147.3% | $48.3M -20.7% | $60.9M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $125.7M +3.7% | $121.2M +34.0% | $90.5M +274.9% | $24.1M +14.7% | $21.0M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$57.8M -110.7% | -$27.4M -42.6% | -$19.2M -309.6% | -$4.7M -633.6% | -$640.0K | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $17.3M +25.6% | $13.8M +35.3% | $10.2M +42.3% | $7.2M +11.1% | $6.4M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$5.9M +91.8% | -$72.7M -200.4% | -$24.2M -447.3% | -$4.4M +33.3% | -$6.6M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $11.6M +157.9% | -$20.1M +62.7% | -$53.9M -590.9% | -$7.8M -200.5% | -$2.6M | $592.6M | $1.3B | $626.2M |
| Inventory | -$16.1M +71.2% | -$55.9M -662.0% | $10.0M +147.2% | -$21.1M -960.1% | $2.5M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$402.0K -102.9% | $13.8M -26.2% | $18.6M -7.9% | $20.2M +1011.2% | -$2.2M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$1.1M +89.9% | -$10.4M -1057.1% | $1.1M -74.2% | $4.2M +198.7% | -$4.3M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $1.1B +10833.4% | $9.8M +46.8% | $6.7M +373.6% | -$2.4M | $0 | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $58.2M +65.2% | $35.3M -14.0% | $41.0M -39.7% | $68.0M -16.1% | $81.1M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$104.6M +6.1% | -$111.4M -69.4% | -$65.8M -169.2% | -$24.4M +8.5% | -$26.7M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $5.1M +4599.1% | $108.0K -99.1% | $12.5M +132.4% | -$38.7M +23.7% | -$50.8M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 +100.0% | -$12.5M +97.0% | -$415.9M +47.5% | -$792.7M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $325.0K -99.6% | $82.0M -69.3% | $266.8M -30.1% | $381.8M -50.1% | $764.6M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$99.2M -238.4% | -$29.3M -114.6% | $201.0M +306.8% | -$97.2M +7.9% | -$105.6M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$321.0K +23.6% | -$420.0K +99.6% | -$100.0M | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $2.2M -8.7% | $2.5M +105.5% | $1.2M -84.9% | $7.9M -77.1% | $34.6M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$3.5M -2882.2% | -$118.0K +99.4% | -$19.3M -1621.1% | -$1.1M -3.0% | -$1.1M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$1.6M -183.3% | $1.9M +101.6% | -$118.1M -1833.2% | $6.8M -79.7% | $33.5M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $942.0K +287.6% | -$502.0K +90.4% | -$5.2M +40.4% | -$8.8M -3414.8% | $264.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$41.6M -664.5% | $7.4M -93.8% | $118.8M +481.5% | -$31.1M -433.5% | $9.3M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$46.4M +39.1% | -$76.2M -208.0% | -$24.7M -156.7% | $43.6M -19.8% | $54.4M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.71B
NovoCure Limited
NASDAQ:NVCR
$1.66B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.26B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.10B
OPKO Health, Inc.
NASDAQ:OPK
$1.07B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
CONMED Corporation
NYSE:CNMD
$982.01M
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$862.29M
Tilray Brands, Inc.
NASDAQ:TLRY
$560.34M
Upstream Bio, Inc.
NASDAQ:UPB
$339.04M
SEC Filings
Recent regulatory filings
No filings found.
Does NEOG generate free cash flow?
Neogen Corporation (NEOG) generated -$46,351,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does NEOG produce?
Operating cash flow was $58.24M, before capital expenditures of $104.59M.
Explore More
Continue the stock analysis
Jump to another research area for this company.